Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Rituximab and CHOP in PTLD (PTLD-1/3)
NCT00590447Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2006
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of rituximab in lymphoproliferative disorder (LPD), sponsored by Charité – Universitätsmedizin Berlin. Started Dec 2006; status: completed.
02
Drugs
rituximab
03
Conditions
lymphoproliferative disorder (LPD)
Beyond the preview
Go deeper on NCT00590447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00590447.